MDMB-BINACA
Tools
Actions
Allgemein
Print/export
In other projects
Appearance
From Wikipedia, the free encyclopedia
Chemical compound
![]() | |
Identifiers | |
---|---|
| |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C19H27N3O3 |
Molar mass | 345.443 g·mol−1 |
3D model (JSmol) | |
| |
|
MDMB-BINACA (MDMB-BUTINACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first identified in Sweden in May 2023. It has a similar chemical structure to potent cannabinoid agonists previously reported such as ADB-BUTINACA and MDMB-5'Br-BUTINACA, and is believed to have similar effects.[1]
See also
[edit]References
[edit]- ^ "New psychoactive substances - the current situation in Europe" (PDF). European Drug Report. European Union Drugs Agency (EUDA). 2024.
Receptor (ligands) |
| ||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Transporter (modulators) |
| ||||||||||||||||||||||||||||||
Enzyme (modulators) |
| ||||||||||||||||||||||||||||||
Others |
| ||||||||||||||||||||||||||||||
|
![]() | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
Hidden categories:
- Articles with short description
- Short description with empty Wikidata description
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- All stub articles